Workflow
Novo Nordisk to buy Akero for up to $5.2 billion for promising liver drug
Yahoo Financeยท2025-10-09 11:25

STOCKHOLM (Reuters) -Novo Nordisk (NVO) said on Thursday it would buy U.S.-based Akero Therapeutics (AKRO) for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's new CEO to boost growth. Shares of Akero jumped more than 18% in premarket trading, while Novo's Denmark-listed shares were down nearly 2%. The deal underscores new Novo Nordisk CEO Mike Doustdar's efforts to revive sales growth and fend off intense competition from U.S. riv ...